Maria Palasis, Lyra Therapeutics CEO

Lyra touts pos­i­tive topline PhII da­ta for chron­ic rhi­nos­i­nusi­tis drug

Lyra Ther­a­peu­tics de­buted pos­i­tive topline da­ta this morn­ing for one of its lead pro­grams, LYR-220, which aims to treat chron­ic rhi­nos­i­nusi­tis in pa­tients who still have the dis­ease even af­ter si­nus surgery.

The com­pa­ny said it met the Phase II tri­al’s pri­ma­ry end­point and showed sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment through the 24-week tri­al. The pri­ma­ry end­point was safe­ty, with no se­ri­ous ad­verse events re­port­ed. The most com­mon­ly re­port­ed ad­verse events were si­nusi­tis, na­sopharyn­gi­tis, bron­chi­tis and Covid-19.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.